The global Acute Myeloid Leukemia (AML) Therapeutics Market is projected to grow from USD 3.8 billion in 2025 to USD 10.1 billion by 2036, registering a CAGR of 9.2% between 2026 and 2036, according to a new report by Fact.MR. The market is expected to create an absolute dollar opportunity of approximately USD 5.9 billion, expanding nearly 2.4 times its value over the forecast period. The growth trajectory reflects the increasing shift toward genomics-driven treatment strategies, targeted therapies, and personalized medicine approaches that are transforming the management of acute myeloid leukemia worldwide.
As healthcare providers increasingly adopt molecular diagnostics and mutation-based treatment selection, AML therapeutics are evolving from traditional chemotherapy-focused regimens toward highly individualized treatment pathways designed to improve patient outcomes and reduce disease recurrence. Targeted therapies are expected to account for 36% of market share in 2026, making them the largest drug class segment within the AML therapeutics market. The increasing availability of mutation-specific drugs and novel targeted agents is expanding treatment options for patients with genetically defined AML subtypes. These therapies offer enhanced efficacy and improved tolerability compared to conventional treatment approaches.
By disease type, newly diagnosed AML is projected to hold 48% market share in 2026. Initial treatment regimens generate the highest therapy volumes as patients typically begin treatment immediately following diagnosis and risk assessment. Hospitals remain the leading end-user segment, accounting for 55% of market demand, while hospital pharmacies maintain a dominant position with 49% market share due to the complexity of AML therapies.
One of the strongest growth drivers for the market is the increasing availability of therapies for relapsed and refractory AML patients. New oral targeted therapies, menin inhibitors, and mutation-specific treatments are expanding options for patients who previously had limited treatment alternatives. According to Shambhu Nath Jha, Principal Consultant at Fact.MR, "Acute myeloid leukemia therapeutics are becoming more mutation-specific and patient-risk driven. We see demand rising for oral targeted drugs and lower-intensity combinations."
Regional markets display strong growth potential, with South Asia and East Asia emerging as high-growth regions. Among key countries, India is projected to grow at 11.8% CAGR, China at 10.9% CAGR, the United States at 8.7% CAGR, Germany at 7.9% CAGR, and Japan at 7.4% CAGR. The global AML therapeutics market remains highly competitive, with leading pharmaceutical companies focusing on targeted therapies, mutation-specific treatments, and next-generation oncology solutions. Key companies include AbbVie Inc., Genentech (Roche), Astellas Pharma Inc., Syndax Pharmaceuticals, Inc., and Kura Oncology, Inc.
The full report is available at Fact.MR's AML Therapeutics Market Report. A sample report with detailed forecasts and strategic recommendations can be accessed here.
